Exhibit 99.1

MATERIAL CHANGE REPORT

Regulation 51-102 Respecting Continuous Disclosure Obligations

Form 51-102F3

ITEM 1 - NAME AND ADDRESS OF COMPANY

THERATECHNOLOGIES INC.

2310 Alfred-Nobel Boulevard

Montreal, Québec

Canada H4S 2B4

ITEM 2 - DATE OF MATERIAL CHANGE

December 3, 2013

ITEM 3 - NEWS RELEASE

A news release describing this material change was issued on December 3, 2013 on “Marketwire”. A copy of the news release is available on the SEDAR website at www.sedar.com.

ITEM 4 - SUMMARY OF MATERIAL CHANGE

On December 3, 2013, Theratechnologies Inc. (the “Corporation”) announced that it resumed shipment of EGRIFTA^TM (tesamorelin for injection) to EMD Serono, Inc. in the United States.

The Corporation also announced that it was notified by Jubilant HollisterStier (“Jubilant”), its third-party contract manufacturer of tesamorelin, that the strike initiated by Jubilant’s employees at its manufacturing site located in Montreal, Canada, was over.

ITEM 5 - FULL DESCRIPTION OF MATERIAL CHANGE

5.1 Full description of material change

On December 3, 2013, the Corporation announced that it resumed shipment of EGRIFTA^TM (tesamorelin for injection) to EMD Serono, Inc. in the United States.

The Corporation also announced that it was notified by Jubilant, its third-party contract manufacturer of tesamorelin, that the strike initiated by Jubilant’s employees at its manufacturing site located in Montreal, Canada, was over.

5.2 Disclosure for restructuring transactions

Not applicable.

- 2 -

ITEM 6 - RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102

Not applicable.

ITEM 7 - OMITTED INFORMATION

Not applicable.

ITEM 8 - EXECUTIVE OFFICER

For further information, contact Jocelyn Lafond, Vice President, Legal Affairs, and Corporate Secretary of the Corporation at (514) 336-4804, ext. 288.

ITEM 9 - DATE OF REPORT

December 9, 2013.